Orga**ids Grown from Patient Tumors to Help with Cancer Drug Selection
 

Orga**ids Grown from Patient Tumors to Help with Cancer Drug Selection
[IMG]http://cdn.medgadget.com/wp-content/uploads/2015/05/orga**ids-for-drug-screening.jpg[/IMG]

Since accurately picking ***** to fight patients’ unique tumor mutations remains in large part a guessing game, researchers have been working on finding better approaches. An international team of investigators has developed a way of growing living orga**ids from patients’ own tumor cells for use as a testing platform to discover which ***** work before trying them directly on the patients.

Orga**ids resemble the original tumors much better than cell lines, having a 3D structure, a variety of cells, and similar growth characteristics. In the study published in journal Cell, the researchers grew orga**ids from colorectal cancer biopsies taken from 20 patients. They sequenced the DNA of the orga**ids as well, as well as the original tumors, comparing how the pairs change over time. They discovered that similar mutations occur in the cancers and their corresponding orga**ids, pointing to the use of orga**ids as an*accurate platform for drug selection.

Some details from the study abstract:

In Rspondin-based 3D cultures, Lgr5 stem cells from*multiple organs form ever-expanding epithelial orga**ids that retain their tissue identity. We report the establishment of tumor orga**id cultures from 20 consecutive colorectal carci**ma (CRC) patients. For most, orga**ids were also generated from adjacent **rmal tissue. Orga**ids closely recapitulate several properties of the original tumor. The spectrum of genetic changes within the “living biobank” agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor orga**ids are amenable to high-throughput drug screens allowing detection of gene-drug associations. As an example, a single orga**id culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than inAPC. Orga**id tech**logy may fill the gap between cancer genetics and patient trials, complement cell-line- and xe**graft-based drug studies, and allow personalized therapy design.

Study in journal*Cell: Prospective Derivation of a Living Orga**id Biobank of Colorectal Cancer Patients…

Source: Cell Press…

The post Orga**ids Grown from Patient Tumors to Help with Cancer Drug Selection appeared first on Medgadget.

http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs http://feeds.feedburner.com/~ff/Medg...M4:gIN9vFwOqvQ
http://feeds.feedburner.com/~r/Medgadget/~4/TRPQwXy_ufs